share_log

Stifel Maintains Buy on 10x Genomics, Lowers Price Target to $53

Benzinga ·  May 1 09:01

Stifel analyst Daniel Arias maintains 10x Genomics (NASDAQ:TXG) with a Buy and lowers the price target from $63 to $53.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment